Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Novel approaches for MPNs

Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, describes novel developments in the treatment of myloproliferative neoplasms (MPNs) including the development of IMG-7289 for essential thrombocythemia (ET) and myelofibrosis as well as studies evaluating ropeginterferon alfa-2b for both ET and polycythemia vera. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).